Merck & Company, Inc. (new) (MRK) Covered Calls

Merck & Company, Inc. (new) covered calls Merck & Co., Inc. is a global healthcare leader providing innovative prescription medicines, vaccines, and animal health products. The company is a dominant force in oncology via its immunotherapy platform and holds a major presence in infectious diseases and cardiovascular health. Operating in over 140 countries, Merck focuses on high-value drug discovery and advanced biologic therapies to address significant unmet medical needs across the globe.

You can sell covered calls on Merck & Company, Inc. (new) to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for MRK (prices last updated Fri 4:16 PM ET):

Merck & Company, Inc. (new) (MRK) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
121.41 +2.17 121.10 122.83 10.0M 16 296
Covered Calls For Merck & Company, Inc. (new) (MRK)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 121 1.56 121.27 -0.2% -9.1%
Mar 20 120 4.65 118.18 2.3% 23.3%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

Merck & Co., Inc. (MRK), known as MSD outside the United States and Canada, is a research-intensive biopharmaceutical leader. As of early 2026, the company has successfully transitioned into a diversified powerhouse, moving beyond its historical reliance on a single oncology blockbuster. Its operations are built around four strategic pillars:

  1. Oncology: Merck remains the global leader in immuno-oncology. Its flagship PD-1 inhibitor, Keytruda, is approved for dozens of indications. In late 2025, the company launched "Keytruda Qlex," a subcutaneous formulation that improves patient convenience and extends the franchise's lifecycle. This segment is bolstered by a massive antibody-drug conjugate (ADC) pipeline developed through multi-billion dollar partnerships.
  2. Vaccines: The company is a dominant force in preventive medicine. Gardasil and Gardasil 9, which prevent cancers caused by HPV, remain top-tier global products. Additionally, Merck recently launched Capvaxive, a 21-valent pneumococcal conjugate vaccine that provides broader protection for adults than previous industry standards.
  3. Cardiovascular and Immunology: Following the acquisitions of Acceleron and Prometheus, Merck has built a world-class specialty franchise. Winrevair, a first-in-class therapy for pulmonary arterial hypertension, has become a foundational treatment. In immunology, the company is advancing MK-7240 for ulcerative colitis and Crohn’s disease into late-stage global trials.
  4. Animal Health: One of the largest animal health businesses in the world, this segment provides a balanced revenue stream across livestock and companion animals, featuring the popular Bravecto line of parasiticides.

Competitive Landscape

The 2026 pharmaceutical environment is characterized by intense competition in high-growth areas like obesity, oncology, and next-generation vaccines:

  1. Oncology and Immunology Rivals: Merck’s primary rival in the PD-1 space is Bristol-Myers Squibb (Opdivo). It also competes with AbbVie and Novartis for leadership in specialized immunology and targeted cancer therapies.
  2. Vaccine Competitors: In the race for adult and pediatric immunization, Merck vies for market share against GSK and Pfizer, particularly in the competitive pneumococcal and RSV markets.
  3. Cardiometabolic Peers: As Merck expands its oral PCSK9 and metabolic programs, it increasingly faces Eli Lilly and Company and Novo Nordisk. It also monitors high-scale biologic competitors like Samsung Biologics, which provides significant manufacturing pressure in the biosimilar space.

Strategic Outlook and Innovation

Entering February 2026, Merck is executing a "Pipeline-Driven Resilience" strategy. A major focus this year is the full commercial integration of its oral PCSK9 inhibitor, MK-0616, which aims to revolutionize cholesterol management with a convenient daily pill. Innovation is further driven by the "Merck Digital Lab," which utilizes "Agentic AI" to simulate clinical trial outcomes and optimize manufacturing yields for complex biologics. Strategically, the company is leveraging its $15 billion in annual free cash flow to pursue "bolt-on" acquisitions in the $1 billion to $10 billion range, specifically targeting neuroscience and metabolic health. With a strong 2026 guidance despite near-term headwinds in certain international vaccine markets, Merck is positioned to maintain its status as one of the most profitable and innovation-led healthcare entities in the global market.